Xinrong Tian

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji et al. · Nature · 2012 · 1.8K citations

Ezh2 Inhibition, Lymphoid Neoplasia, Hematological Malignancy +10

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Sharad K. Verma, Xinrong Tian, Louis V. LaFrance et al. · ACS Medicinal Chemistry Letters · 2012 · 373 citations · Full text

Histone Modifications, Drug Discovery Program, Engineering +18

Toluene Dioxygenase-Mediated <i>cis</i>-Dihydroxylation of Aromatics in Enantioselective Synthesis. Asymmetric Total Syntheses of Pancratistatin and 7-Deoxypancratistatin, Promising Antitumor Agents¹

Tomáš Hudlický, Xinrong Tian, Kurt Königsberger et al. · Journal of the American Chemical Society · 1996 · 157 citations

Medicinal Chemistry, Biosynthesis, Engineering +15

First Total Synthesis of (+)-Pancratistatin: An Unusual Set of Problems

Xinrong Tian, Tomáš Hudlický, K. KOENIGSBERGER · Journal of the American Chemical Society · 1995 · 149 citations

Combinatorial Chemistry, Quantitative Methods, Bioorganic Chemistry +20